Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Food safety

This article was originally published in The Tan Sheet

Executive Summary

Texas A&M Chemical Engineering Department awarded two-year grant for "Development of Cell and Nanoparticle-Based Sensors for BSE," CFSAN announces Oct. 5. First-year funding is $100,635 for research aimed at developing tools to detect BSE/TSE in CFSAN-regulated products. FDA, USDA announce additional funding of almost $712,000 to five other universities for research on ready-to-eat foods, listeria cross-contamination, water irrigation quality and methods. FDA issued a request for applications on food safety research in May (1"The Tan Sheet" May 28, p. 10)

You may also be interested in...



Dietary Supplement, Foods BSE Detection Research Funds Announced By FDA

FDA is requesting grant applications for development of "practical analytical techniques" to detect the presence of bovine spongiform encephalopathy and transmissible spongiform encephalopathies in dietary supplements, infant formula and other end products.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel